Synopsis

It has long been thought that PTPs (protein tyrosine phosphatases) normally function as tumour suppressors. Recent high-throughput mutational analysis identified loss-of-function mutations in six PTPs in human colon cancers, providing critical cancer genetics evidence that PTPs can act as tumour suppressor genes. PTPRT (protein tyrosine phosphatase receptor-T), a member of the family of type IIB receptor-like PTPs, is the most frequently mutated PTP among them. Consistent with the notion that PTPRT is a tumour suppressor, PTPRT knockout mice are hypersensitive to AOM (azoxymethane)-induced colon cancer. The present review focuses on the physiological and pathological functions of PTPRT as well as the cellular pathways regulated by this phosphatase.

Key words: cell adhesion, colon cancer, protein tyrosine phosphatase receptor-T (PTPRT), receptor protein tyrosine phosphatases types IIB, tumour suppressor

INTRODUCTION

Although protein tyrosine kinases, such as JAK (Janus kinase), BCR-Abl and Src [1,2], have been long known to serve as oncogenes the role that their cellular counterpart – PTPs (protein tyrosine phosphatases) – could play in cancer progression had not been extensively explored. The PTP superfamily, which regulates a multitude of signalling pathways, is divided into either ‘receptor-like’ [RPTP (receptor protein tyrosine phosphatase)] or ‘non-transmembrane’ [3]. Recently, a high-throughput mutational analysis of all PTPs identified six PTPs to be mutated in colon cancer [4]. Among them, PTPRT (protein tyrosine phosphatase receptor-T), also known as PTPρ, is the most frequently mutated tyrosine phosphatase. In the present review, we focus on the physiological and pathological functions of PTPRT as well as the cellular pathways regulated by this phosphatase.

DOMAIN STRUCTURE OF PTPRT

PTPRT belongs to the type IIB RPTP subfamily that consists of PTPRK, PTPRM, PTPRT and PTPRU (protein tyrosine phosphatase receptor-K, -M, -T and -U; PTPRU is frequently referred to as PCP-2). All four type IIB RPTPs share common domain architecture: an extracellular domain, a transmembrane domain, a juxtamembrane region and two phosphatase domains (Figure 1). The extracellular domains of type II RPTPs have high-sequence identities [3]: all consist of an MAM (meprin/A5/PTPμ) domain, an Ig domain and four FNIII (fibronectin type III) repeats (Figure 1). The MAM domain is suggested to play a role in protein dimerization. The Ig domain is a disulfide structure that is found in many cell-surface proteins and has been shown to mediate homophilic and heterophilic interactions between cell adhesion molecules. The FNIII motif was originally identified in the extracellular matrix protein fibronectin and later found to be present in many cell adhesion molecules [3]. Intracellular domains include the juxtamembrane domain, which has similarity to cadherin domains [3,5], and two phosphatase domains, D1 and D2. The juxtamembrane domain was specifically identified as being responsible for many of the sequence differences between the four type Ib family members, providing specificity in signal transduction [5] and potentially needed for catalytic activity in some family members [6,7]. The phosphatase domain D1 is actively responsible for the phosphatase activity of type Ib members, while the ‘pseudophosphatase’ domain D2, although catalytically inactive, is thought to be important for regulation [6].
PTPRT AS A TUMOUR SUPPRESSOR

PTPRT is mutated in colon, lung, stomach and skin (melanoma) cancers. Several lines of genetic evidence suggest that PTPRT normally functions as a tumour suppressor gene: first, a significant fraction of the mutations found in tumour samples are nonsense and insertion and deletion mutations, resulting in premature truncation of PTPRT and therefore loss of its function [4]. Secondly, consistent with Knudson’s Two-Hit Hypothesis for the inactivation of tumour suppressor activity [2,8,9], approximately one-third of the tumours with PTPRT mutations harbour two different mutations in one tumour [4]. Thirdly, many of the tumour-derived missense mutations in either the D1 or the D2 phosphatase domains lead to reduced phosphatase activity of PTPRT [4]; similarly, such mutations in the extracellular domain result in defective cell adhesion [10,11]. Fourthly, overexpression of PTPRT activity inhibited cell growth, acting as a putative tumour suppressor in cancer cell culture [4]. Most importantly, knockout mice lacking both alleles of PTPRT, grown in a strain normally resistant to AOM (azoxymethane)-induced colon cancer, became highly susceptible to AOM-induced adenomas (Figure 2) [12]. Another large-scale screen also independently identified PTPRT as a putative tumour suppressor: after mobilizing transposable elements in mouse somatic cells, the authors documented which insertion sites led to tumour formation, ultimately including PTPRT in its list [13].

ROLE OF PTPRT IN CELL ADHESION

Similar to PTPRM and PTPRK, we demonstrated that the extracellular domain of PTPRT also mediated homophilic cell–cell adhesion [10]. This homophilic interaction is very specific, as the extracellular part of PTPRT does not interact with PTPRM, PTPRK or PTPRU [10,14]. The specificity of the homophilic cell–cell adhesion seems to be determined by the MAM and Ig domains, because chimaeric PTPRT that substituted its own MAM or Ig domains for those of PTPRU would not aggregate with cells expressing wild-type PTPRT [14]. Consistent with the notion that the MAM and Ig domains are critical for PTPRT’s cell adhesion function, deletion mutants devoid of either domain abolish its ability to mediate cell aggregation [10]. Surprisingly, we found that the four FNIII domains of PTPRT are also required for its cell–cell adhesion function [11]. Importantly, all the tumour-derived mutations located in the extracellular domains of PTPRT show defects in cell–cell adhesion [10,11].

The crystal structures of PTPRM revealed some clues to how PTPRT mutations affect cell–cell adhesion, as these mutated residues in PTPRT were able to be correlated with key amino acids in PTPRM [15,16]. According to these data, some of these mutations were predicted to disturb the structure as a whole, affecting the overall folding patterns, the stability of the extracellular portion of the protein or the ability for the protein to correctly localize to the membrane [16]. However, one mutated residue in the Ig domain was thought to be specifically responsible for changing the capability for protein–protein interaction, underscoring the importance of this function in normal physiology [15]. Moreover, crystal structures also inform the importance of the ectodomain in dimerization as well as ensuring correct spacing between adjacent cells at adherens junctions so that interactions with substrates can occur properly [16].

Consistent with the role of PTPRT in cell–cell adhesion, Besco et al. [17] showed that PTPRT interacts with E-cadherin (endothelial cadherin). The authors then showed that this interaction leads to E-cadherin dephosphorylation, affecting the stability of junctional complexes [17].

PTPRT IN SIGNALLING PATHWAYS

Identification of the substrates of PTPRT is an important step to understand its tumour suppressor function. Since PTPRT’s phosphatase activity is often attenuated in cancers, proteins that retain phosphorylated tyrosine residues when PTPRT is mutated in the crucial D1 and D2 domains may be involved in tumorigenesis. Studies to this end ultimately identified proteins that had been previously speculated to be proto-oncogenes, specifically paxillin and STAT3 (signal transducer and activator of transcription 3) [12,18]. In each case, a phosphopeptide profile was collected from wild-type cancer cells and cells from the same lineage that express either the intracellular fragment of PTPRT (which contains
PTPRT serves as tumour suppressor

Figure 2  PTPRT-knockout mice are hypersensitive to AOM-induced colon tumours

(A) Schematic of PTPRT targeting strategy. The exon 22, which encoded the phosphatase catalytic motif of PTPRT, was deleted. (B) Southern blotting of genomic DNA from mice with indicated PTPRT genotypes. Arrowhead indicates the targeted alleles. (C) Gross morphology of two tumours (arrowheads) in a PTPRT−/− mouse (right) compared with a colon of a PTPRT+/+ wild-type (WT) mouse. (D) Representative images of haematoxylin and eosin staining of AOM-induced tumours. (E) Numbers of colon tumours developed in each of the PTPRT+/+, +/- and −/− C57BL/6J mice (n = 20 in each group). Each circle, square or triangle represents one mouse. (C) and (E) are reproduced from [12] with permission.

both the phosphatase domains needed for enzymatic activity) or the extracellular fragment (which lacks such activity). Those phosphopeptides that still had tyrosine phosphorylation in the absence of a functional copy of PTPRT warranted further review as possible substrates.

This finding of paxillin as a putative substrate for PTPRT complements the canonical function of the type IIB family members, which often interact with adherens junction proteins [17], as paxillin is known to be involved in cell–cell adhesion [19].

We have shown that PTPRT was responsible for dephosphorylating Tyr88 [12]. The importance of Tyr88 phosphorylation was especially seen in xenograft models, where cancer cells with mutated Tyr88 residues (a ‘knock-in’ cell line with phenylalanine substituted for Tyr88 – Y88F – prevented phosphorylation from occurring) were not able to grow xenografts [12]. Similarly, the Y88F mutants in cell lines experienced reduction in anchorage-independent growth and cell migration, as well as changes in Akt (also known as protein kinase B), SHP2 (short heterodimer partner 2) and p130CAS signalling due to alterations in their respective phosphorylation levels [12]. Consistent with the premise that phospho-Tyr88 paxillin plays an oncogenic role, this phosphorylated residue is up-regulated in majority of human colon cancer tissues in comparison with the matched adjacent normal tissues [12].

Similarly, PTPRT was also found to reverse Tyr705 phosphorylation on STAT3, a modification associated with STAT3 activation [18]. Substrate-trapping assays reinforced this finding. Then, we showed that PTPRT’s phosphatase activity was crucial in regulating STAT3’s translocation into the nucleus and activation of target genes, many of which are involved in cell survival and tumorigenesis [especially BCL-XL and SOCS3 (suppressor of cytokine signalling 3)] [18].
ROLE OF PTPRT IN NEUROLOGICAL DEVELOPMENT AND ITS REGULATION

McAndrew et al. [20] discovered PTPRT due in part to the role that many other RPTPs play in neural physiology [21]. The authors demonstrated that expression of PTPRT was largely limited to the brain and spinal cord. In situ hybridization identified the hippocampus and dentate gyrus as specific areas of the brain, especially in post-migratory cells instead of the dividing and mobile neurons of prenatal nervous system development. Therefore, the authors then hypothesized that PTPRT might be more involved in synaptic regulation rather than nervous system growth and development. Lim et al. [22] delved into this speculation in their study about PTPRT and its regulation. They showed that PTPRT fosters synaptic formation by interacting with a series of synaptic-related proteins (including neurulin family members and neurexin) and binding with other PTPRT molecules on other cells; both interactions occur via PTPRT’s extracellular domains. This paper was also crucial as it explored PTPRT’s regulation, as the authors demonstrate that this activity is attenuated by expression of Fyn kinase (a Src kinase family member), decreasing synapse formation. Specifically, Fyn phosphorylates PTPRT in its catalytic domain, causing inactivating interactions between PTPRT molecules on the same cell, a loss of phosphatase activity and ultimately an inability of PTPRT to interact with its target proteins.

OTHER TYPE IIB FAMILY MEMBERS AS TUMOUR SUPPRESSORS

PTPRT is not the only type IIB family member implicated as a tumour suppressor, as PTPRK, PTPRM and PTPRU are also implicated in tumorigenesis [9]. After first being associated with a known tumour suppressor region, loss of PTPRK function gradually became associated with a variety of cancers. PTPRK was first identified as a possible tumour suppressor in a study that mapped it to the long arm of the sixth chromosome, specifically at 6q22.2–q23.3, a region that had already been known to be deleted in a variety of neoplasms [23]. These data were followed by a microsatellite study of 6q22–6q23 in primary CNS (central nervous system) lymphomas, confirming that PTPRK was the responsible gene [24]. The authors in that paper further investigated the possibility of PTPRK acting as a tumour suppressor, demonstrating that mRNA transcripts were absent and protein expression levels were decreased in tumour samples versus control tissue [24]. Their results also had clinical significance in that decreased PTPRK expression correlated with decreased patient survival, furthering the case that PTPRK is a tumour suppressor [24]. Another study associated PTPRK with HL (Hodgkin Lymphoma): PTPRK [transcription of which depends on TGF-β (transforming growth factor-β)] antagonized the growth of HL cells positive for the Epstein–Barr virus, but this specific subset of HL overcomes PTPRK’s inhibition by down-regulating TGF-β signalling [25]. Moreover, this tumour suppressor role can be extended to skin cancers, as transcriptional levels of PTPRK and PTPRU were decreased in melanoma tumour samples according to data generated from RT–PCR (reverse transcription–PCR) [26] and microarray [27].

Much work has been done to elucidate the role that PTPRM plays in suppressing GBM (glioblastoma multiforme). After identifying a decrease in PTPRM expression in GBM samples (a high-grade astrocytoma) versus low-grade astrocytomas, Burgess et al. [28] decided to investigate the migratory abilities of cells without functional PTPRM, since the classification of GBM as ‘high grade’ depends on the dispersal of its constituent cells. In a wound-scratch assay, cells without PTPRM expression due to shRNA (small-hairpin RNA) knockdown experienced greater migratory capability than cells that expressed PTPRM [28]. A complementary paper showed that, although overexpression of PTPRM was key in decreasing cellular migration, similar results were seen when PTPRM fragments were also knocked down [29]. Other RPTPs are known to be cleaved proteolytically, and the authors identified PTPRM cleavage products in GBM cell lines, one of which translocates to the nucleus; cleavage products were seen preferentially instead of full-length PTPRM in tumour samples [29]. Then, these fragments – still catalytically active – were shown to be important for GBM cell proliferation and movement [29]. Moreover, a subsequent study demonstrated that these fragments are useful diagnostically, as probes against the extracellular fragment were used to detect GBM tumours in vivo [30].

Although one of least studied phosphatases in the RPTP type IIB family, evidence suggests that PTPRU might also be a tumour suppressor. This RPTP is notable for its role in obstructing colon carcinoma development [31]. Particularly, PTPRU antagonizes β-catenin’s transcriptional activation activity, preventing transcription of target genes. As a result, when expressed in a colon carcinoma cell line with increased β-catenin stability, PTPRU resulted in decreased cellular movement and replication, acting as a tumour suppressor. It is worth noting that PTPRU is also mutated in colon cancer tumour samples [32].

CONCLUSIONS

Recent studies have elaborated on the role that RPTP type IIB family members play in suppressing tumour growth, especially PTPRT. Although originally discovered as a primarily neurological protein, PTPRT has been shown to play integral roles in cell adhesion and intracellular signalling, due in part to extensive studies done on its extracellular and intracellular domains respectively. When this normal physiological role becomes abrogated, however, cellular transformation often occurs, demonstrating its importance as a tumour suppressor. Further studies need to be made on PTPRT and its type IIB family members to identify additional phosphatase targets to obtain a better understanding of progression to cancer.
PTPRT serves as tumour suppressor

FUNDING

Our own work was supported by the National Institutes of Health [grant number R01-CA127590].

REFERENCES


Received 17 November 2010; accepted 22 November 2010

Published on the Internet 21 April 2011, doi:10.1042/BSR20100134

www.bioscirep.org / Volume 31 (5) / Pages 303–307

307